CD8A and cancer: While the efficacy of CD40-based cancer vaccines in preclinical models is clear, aside from the dependence on T cells, primarily but not absolutely CD8+ T cells, the mechanism of action of effective therapeutic CD40-based cancer vaccines is still under investigation.